Navigation Links
Over 50% of “Best Heart Hospitals” in U.S. News & World Report Are Certified to Implant the SynCardia Total Artificial Heart

Tucson, Ariz. (PRWEB) August 08, 2013

SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that over half of the top 50 centers honored in U.S. News & World Report’s “Best Hospitals” list for cardiology and heart surgery for 2013-2014, offer the SynCardia temporary Total Artificial Heart.

“The fact that these top U.S. transplant centers offer the SynCardia Total Artificial Heart demonstrates its growing acceptance as the new standard of care for end-stage biventricular heart failure,” said Michael Garippa, SynCardia CEO and President.

In June, U.S. News and World Report published its annual list of “Best Children’s Hospitals” for cardiology and heart surgery. Among the top 10 were seven pediatric centers that offer the SynCardia Total Artificial Heart: #2 Children's Hospital of Philadelphia (CHOP), #3 Texas Children's Hospital, #5 Cincinnati Children's Hospital Medical Center, #11 Children's Hospital of Wisconsin, #26 Mattel Children's Hospital UCLA, #32 Shands Hospital for Children at the University of Florida and #34 Phoenix Children's Hospital.

As of July 18, SynCardia Certified Centers worldwide have performed a record-breaking 100 implants of the SynCardia Total Artificial Heart in 2013. This milestone was achieved three months earlier than in 2012, when the 100th implant was performed on Oct. 16. Worldwide, there have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 315 patient years of life.

There are currently 87 SynCardia Certified Centers worldwide, including 48 in the U.S. An additional 33 centers are currently completing SynCardia’s four-phase certification program.


About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 315 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that eliminates the symptoms and source of end-stage biventricular failure.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"

In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
2. Indigo Biosystems Among “Best Places to Work” in Indiana
3. Probiotic Action The “Best Acne Treatment” Shares New Insight on the Future of Preventing the Spread of Acne Causing Germs
4. 7 SynCardia Certified Centers Honored Among “Best Children’s Hospitals” for Cardiology and Heart Surgery by U.S. News & World Report
5. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
6. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
7. Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise
8. Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery
9. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
10. Slovenias 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the Freedom® Portable Driver
11. New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation
Post Your Comments:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):